Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Recommendations
3.1.1. Recommendation 1: Switching to AOM in Acute Patients from Oral Aripiprazole for Enhancing Treatment Effectiveness
- For acute patients on oral aripiprazole ≤15 mg, the recommended starting dose of AOM was 300 mg (LoA = 90%).
- Experts recommended maintaining the same dose of oral aripiprazole during the overlap period for acute patients receiving oral aripiprazole ≤15 mg (LoA = 80%).
3.1.2. Recommendation 2: Switching to AOM in Acute Patients on Oral Atypical Antipsychotics (Excluding Aripiprazole and Clozapine) for Enhancing Treatment Effectiveness
- At least 3–7 days of oral aripiprazole was recommended to establish tolerability for aripiprazole-naïve patients (LoA = 100%).
3.1.3. Recommendation 3: Switching to AOM in Acute Patients on Oral Clozapine for Enhancing Treatment Effectiveness
- At least 3–7 days of oral aripiprazole is recommended to establish tolerability for aripiprazole-naïve patients (LoA = 100%).
- After successful switching to AOM (more than 4–5 doses), concomitant clozapine can be continued at a lower dose (LoA = 90%).
3.1.4. Recommendation 4: Switching to AOM in Stable Patients on Oral Aripiprazole for Enhancing Treatment Effectiveness
- For stable patients on oral aripiprazole ≤10 mg, the recommended starting dose of AOM was 300 mg (LoA = 97%).
- For stable patients on oral aripiprazole of 11–15 mg (LoA = 57%) and of 16–30 mg (LoA = 80%), the majority of experts recommended decreasing the dose of aripiprazole when switching to AOM.
3.1.5. Recommendation 5: Switching to AOM in Stable Patients on Oral Atypical Antipsychotics (Excluding Aripiprazole and Clozapine) for Enhancing Treatment Effectiveness
- At least 3–7 days of oral aripiprazole is recommended to establish tolerability for aripiprazole-naïve patients (LoA = 100%).
- The starting dose of AOM should correspond to the current oral dose of atypical antipsychotics as converted to an equivalent dose of oral aripiprazole (LoA = 80%).
3.1.6. Recommendation 6: Switching to AOM in Stable Patients on Oral Clozapine for Enhancing Treatment Effectiveness
- At least 3–7 days of oral aripiprazole is recommended to establish tolerability for aripiprazole-naïve patients (LoA = 97%).
- After successful switching to AOM (more than 4–5 doses), concomitant clozapine can be continued at a lower dose (LoA = 97%).
3.1.7. Recommendation 7: Switching to AOM in Acute Patients on other LAIs for Enhancing Treatment Effectiveness
- At least 3–7 days of oral aripiprazole is recommended to establish tolerability for aripiprazole-naïve patients (LoA = 100%).
- When switching from 1-month LAI paliperidone palmitate to AOM, concomitant oral aripiprazole for at least 2 weeks is recommended (LoA = 80%).
3.1.8. Recommendation 8: Switching to AOM in Stable Patients on Other LAIs for Enhancing Treatment Effectiveness
- At least 3–7 days of oral aripiprazole is recommended to establish tolerability for aripiprazole-naïve patients (LoA = 100%).
3.1.9. Recommendation 9: For Pregnant or Lactating Patients on AOM
- The majority of experts recommended that if the benefits of continuing treatment outweigh the risks, AOM could be continued for pregnant patients after education of the potential risks (LoA = 80%).
- The majority of experts recommended that if the benefits of continuing treatment outweigh the risks, AOM could be continued for lactating patients after education of the potential risks (LoA = 80%).
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Marder, S.R.; Cannon, T.D. Schizophrenia. N. Engl. J. Med. 2019, 381, 1753–1761. [Google Scholar] [CrossRef] [PubMed]
- Robinson, D.; Woerner, M.G.; Alvir, J.M.; Bilder, R.; Goldman, R.; Geisler, S.; Koreen, A.; Sheitman, B.; Chakos, M.; Mayerhoff, D.; et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56, 241–247. [Google Scholar] [CrossRef]
- Kishimoto, T.; Hagi, K.; Nitta, M.; Leucht, S.; Olfson, M.; Kane, J.M.; Correll, C.U. Effectiveness of Long-Acting Injectable vs. Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophr. Bull 2018, 44, 603–619. [Google Scholar] [CrossRef] [Green Version]
- Shirley, M.; Perry, C.M. Aripiprazole (ABILIFY MAINTENA(R)): A review of its use as maintenance treatment for adult patients with schizophrenia. Drugs 2014, 74, 1097–1110. [Google Scholar] [CrossRef]
- Ostuzzi, G.; Bertolini, F.; Del Giovane, C.; Tedeschi, F.; Bovo, C.; Gastaldon, C.; Nosé, M.; Ogheri, F.; Papola, D.; Purgato, M.; et al. Maintenance Treatment with Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. Am. J. Psychiatry 2021, 178, 424–436. [Google Scholar] [CrossRef] [PubMed]
- Fagiolini, A.; Alfonsi, E.; Amodeo, G.; Cenci, M.; Di Lella, M.; Farinella, F.; Ferraiuolo, F.; Fraguas, D.; Loparco, N.; Gutierrez-Rojas, L.; et al. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: Expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opin. Drug Saf. 2016, 15, 449–455. [Google Scholar] [CrossRef] [PubMed]
- Wong, M.M.C.; Chung, A.K.K.; Yeung, T.M.H.; Wong, D.T.W.; Lee, C.K.; Lai, E.; Chan, G.F.Y.; Mak, G.K.L.; Wong, J.O.Y.; Ng, R.M.K.; et al. Consensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong. Intern. Med. J. 2020, 50 (Suppl. 3), 6–14. [Google Scholar] [CrossRef] [PubMed]
- Eubank, B.H.; Mohtadi, N.G.; Lafave, M.R.; Wiley, J.P.; Bois, A.J.; Boorman, R.S.; Sheps, D.M. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med. Res. Methodol. 2016, 16, 56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leucht, S.; Samara, M.; Heres, S.; Patel, M.X.; Woods, S.W.; Davis, J.M. Dose equivalents for second-generation antipsychotics: The minimum effective dose method. Schizophr. Bull. 2014, 40, 314–326. [Google Scholar] [CrossRef] [Green Version]
- Mallikaarjun, S.; Salazar, D.E.; Bramer, S.L. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharm. 2004, 44, 179–187. [Google Scholar] [CrossRef] [PubMed]
- Mallikaarjun, S.; Kane, J.M.; Bricmont, P.; McQuade, R.; Carson, W.; Sanchez, R.; Forbes, R.A.; Fleischhacker, W.W. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study. Schizophr. Res. 2013, 150, 281–288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kane, J.M.; Peters-Strickland, T.; Baker, R.A.; Hertel, P.; Eramo, A.; Jin, N.; Perry, P.P.; Gara, M.; McQuade, R.D.; Carson, W.H.; et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: Findings from a 12-week, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2014, 75, 1254–1260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leucht, S.; Crippa, A.; Siafis, S.; Patel, M.X.; Orsini, N.; Davis, J.M. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am. J. Psychiatry 2020, 177, 342–353. [Google Scholar] [CrossRef]
- Chan, S.K.W.; Chan, H.Y.V.; Honer, W.G.; Bastiampillai, T.; Suen, Y.N.; Yeung, W.S.; Lam, M.; Lee, W.K.; Ng, R.M.K.; Hui, C.L.M.; et al. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders. Schizophr. Bull. 2021, 47, 485–494. [Google Scholar] [CrossRef]
- Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45, 789–796. [Google Scholar] [CrossRef] [PubMed]
- Liang, C.S.; Ho, P.S.; Shen, L.J.; Lee, W.K.; Yang, F.W.; Chiang, K.T. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: A randomized, double-blind, crossover study. Schizophr. Res. 2010, 119, 138–144. [Google Scholar] [CrossRef] [PubMed]
- Lewis, S.W.; Barnes, T.R.; Davies, L.; Murray, R.M.; Dunn, G.; Hayhurst, K.P.; Markwick, A.; Lloyd, H.; Jones, P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32, 715–723. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siskind, D.; Siskind, V.; Kisely, S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Can. J. Psychiatry 2017, 62, 772–777. [Google Scholar] [CrossRef] [PubMed]
- Tiihonen, J.; Taipale, H.; Mehtala, J.; Vattulainen, P.; Correll, C.U.; Tanskanen, A. Association of Antipsychotic Polypharmacy vs. Monotherapy with Psychiatric Rehospitalization Among Adults with Schizophrenia. JAMA Psychiatry 2019, 76, 499–507. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siskind, D.J.; Lee, M.; Ravindran, A.; Zhang, Q.; Ma, E.; Motamarri, B.; Kisely, S. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust. N. Z. J. Psychiatry 2018, 52, 751–767. [Google Scholar] [CrossRef] [Green Version]
- McAllister-Williams, R.H.; Baldwin, D.S.; Cantwell, R.; Easter, A.; Gilvarry, E.; Glover, V.; Green, L.; Gregoire, A.; Howard, L.M.; Jones, I.; et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J. Psychopharmacol. 2017, 31, 519–552. [Google Scholar] [CrossRef] [PubMed]
- Boden, R.; Lundgren, M.; Brandt, L.; Reutfors, J.; Andersen, M.; Kieler, H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: Population based cohort study. BMJ 2012, 345, e7085. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lin, H.C.; Chen, I.J.; Chen, Y.H.; Lee, H.C.; Wu, F.J. Maternal schizophrenia and pregnancy outcome: Does the use of antipsychotics make a difference? Schizophr. Res. 2010, 116, 55–60. [Google Scholar] [CrossRef] [PubMed]
- Petersen, I.; McCrea, R.L.; Sammon, C.J.; Osborn, D.P.; Evans, S.J.; Cowen, P.J.; Freemantle, N.; Nazareth, I. Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records. Health Technol. Assess. 2016, 20, 1–176. [Google Scholar] [CrossRef] [Green Version]
Patient Status | Current Medication | Consensus Recommendation |
---|---|---|
Acute | Oral aripiprazole | Recommendation 1 |
Oral atypical antipsychotics (excluding aripiprazole and clozapine) | Recommendation 2 | |
Oral clozapine | Recommendation 3 | |
Stable | Oral aripiprazole | Recommendation 4 |
Oral atypical antipsychotics (excluding aripiprazole and clozapine) | Recommendation 5 | |
Oral clozapine | Recommendation 6 | |
Acute | Long-acting injectable antipsychoitcs | Recommendation 7 |
Stable | Long-acting injectable antipsychotics | Recommendation 8 |
Pregnant or Lactating | Aripiprazole long-acting once-monthly | Recommendation 9 |
Recommendation 1: Switching to AOM in Acute Patients from Oral Aripiprazole for Enhancing Treatment Effectiveness. | Practice Option | LoA |
Treatment initiation with AOM 300 mg is recommended for patients whose current dose of oral aripiprazole is lower than 15 mg. | 90% | |
The majority of experts recommend maintaining 3–4 weeks of concomitant oral aripiprazole treatment when switching to AOM. | 3–4 weeks | 53% |
5–12 weeks | 23% | |
≤2 weeks | 17% | |
≥13 weeks | 7% | |
For patients currently receiving an oral aripiprazole dose of ≤15 mg, it is recommended to maintain the same dose level for concomitant oral aripiprazole treatment when switching to AOM. | 80% | |
For patients currently receiving an oral aripiprazole dose of 16–20 mg, the majority of experts recommend maintaining the same dose level for concomitant oral aripiprazole treatment when switching to AOM. | Maintain | 67% |
Decrease | 33% | |
For patients currently receiving an oral aripiprazole dose of 21–30 mg, the majority of experts recommend decreasing the same dose level for concomitant oral aripiprazole treatment when switching to AOM. | Decrease | 73% |
Maintain | 27% | |
Recommendation 2: Switching to AOM in acute patients on oral atypical antipsychotics (excluding aripiprazole and clozapine) for enhancing treatment effectiveness. | Practice Option | LoA |
At least 3–7 days of prior treatment with oral aripiprazole is recommended for patients who have never been treated with aripiprazole before. | 100% | |
The majority of experts recommend that the starting dose of AOM should be based on the oral aripiprazole dose equivalent to the current dose of oral atypical antipsychotics (please see Table 3). | Based on equivalent oral aripiprazole dose | 67% |
AOM 400 mg preferred | 33% | |
The majority of experts recommend that for patients who cannot tolerate their current oral atypical antipsychotics (excluding aripiprazole and clozapine), they should be switched to oral aripiprazole at a dose equivalent to the current dose of oral atypical antipsychotics (please see Table 3) for concomitant oral therapy when switching to AOM. | Switch to equivalent oral aripiprazole dose | 63% |
Maintain original oral atypical antipsychotics but at reduced dose | 23% | |
Switch to lower oral aripiprazole dose | 10% | |
The majority of experts recommend maintaining 5–12 weeks of concomitant oral atypical antipsychotics (maintaining original olanzapine or quetiapine, or switching to aripiprazole) for patients receiving quetiapine or olanzapine. | 5–12 weeks | 53% |
≥13 weeks | 23% | |
3–4 weeks | 20% | |
Other | 3% | |
Recommendation 3: Switching to AOM in acute patients on oral clozapine for enhancing treatment effectiveness. | Practice Option | LoA |
At least 3–7 days of prior treatment with oral aripiprazole is recommended for patients who have never been treated with aripiprazole before. | 100% | |
The majority of experts recommended starting AOM at a dose of 400 mg. | 400 mg | 77% |
Based on clozapine equivalent oral aripiprazole dose | 20% | |
300 mg | 3% | |
The majority of experts recommended maintaining oral clozapine at the original dose as concomitant medication during the first 4–5 doses of AOM treatment. | Oral clozapine at original dose | 77% |
Oral clozapine at reduced dose | 23% | |
For patients that have achieved stable treatment (more than 4–5 doses) after switching to AOM, concomitant oral medication with clozapine can be continued at a reduced dose. | 90% | |
Recommendation 4: Switching to AOM in stable patients on oral aripiprazole for enhancing treatment effectiveness. | Practice Option | LoA |
Treatment initiation with AOM 300 mg is recommended for patients whose current dose of oral aripiprazole is lower than 10 mg. | 97% | |
For patients currently receiving an oral aripiprazole dose of ≤10 mg, the majority of experts recommend maintaining the same dose level for concomitant oral aripiprazole treatment when switching to AOM. | Maintain | 57% |
Decrease | 43% | |
For patients currently receiving an oral aripiprazole dose of 11–15 mg, the majority of experts recommend decreasing the dose level for concomitant oral aripiprazole treatment when switching to AOM. | Decrease | 57% |
Maintain | 43% | |
For patients currently receiving an oral aripiprazole dose of 16–30 mg, it is recommended to decrease the dose level for concomitant oral aripiprazole treatment when switching to AOM. | 80% | |
Recommendation 5: Switching to AOM in stable patients on oral atypical antipsychotics (excluding aripiprazole and clozapine) for enhancing treatment effectiveness. | Practice Option | LoA |
At least 3–7 days of prior treatment with oral aripiprazole is recommended for patients who have never been treated with aripiprazole before. | 100% | |
The starting dose of AOM should be based on the oral aripiprazole dose equivalent to the current dose of oral atypical antipsychotics (please see Table 3). | 80% | |
The majority of experts recommend maintaining 3–4 weeks of concomitant oral atypical antipsychotics (maintaining original other SDAs or switching to aripiprazole) for patients receiving other SDAs (namely, amisulpride, lurasidone, paliperidone, risperidone, and ziprasidone). | 3–4 weeks | 53% |
≤2 weeks | 30% | |
5–12 weeks | 13% | |
≥13 weeks | 3% | |
The majority of experts recommend maintaining 5–12 weeks of concomitant oral atypical antipsychotics (maintaining original olanzapine or quetiapine, or switching to aripiprazole) for patients receiving quetiapine or olanzapine. | 5–12 weeks | 57% |
3–4 weeks | 27% | |
≥13 weeks | 17% | |
Recommendation 6: Switching to AOM in stable patients on oral clozapine for enhancing treatment effectiveness. | Practice Option | LoA |
At least 3–7 days of prior treatment with oral aripiprazole is recommended for patients who have never been treated with aripiprazole before. | 97% | |
The majority of experts recommended starting AOM at a dose of 400 mg. | 400 mg | 63% |
Based on clozapine equivalent oral aripiprazole dose | 27% | |
300 mg | 10% | |
The majority of experts recommended maintaining oral clozapine at the original dose as concomitant medication during the first 4–5 doses of AOM treatment. | Oral clozapine at original dose | 77% |
Oral clozapine at reduced dose | 23% | |
For patients that have achieved stable treatment (more than 4–5 doses) after switching to AOM, concomitant oral medication with clozapine can be continued at a reduced dose. | 97% | |
Recommendation 7: Switching to AOM in acute patients on other LAIs for enhancing treatment effectiveness. | Practice Option | LoA |
At least 3–7 days of prior treatment with oral aripiprazole is recommended for patients who have never been treated with aripiprazole before. | 100% | |
The majority of experts recommended that the original LAI should be stopped upon initiating AOM treatment. | Stopped upon initiation of AOM | 67% |
Tapered following stable AOM use | 33% | |
The majority of experts recommended that AOM should be initiated prior to the next dose of the original LAI | Prior to the next dose | 67% |
Replace the next dose | 33% | |
The majority of experts recommended starting AOM at a dose of 400 mg. | 400 mg | 63% |
Based on the dose of the original LAI | 37% | |
When switching from LAI risperidone (Risperdal Consta®) to AOM, the majority of experts recommended concomitant oral aripiprazole medication for at least 2 weeks. | Oral aripiprazole for at least 2 weeks | 67% |
No concomitant oral medication needed | 17% | |
Oral risperidone for at least 2 weeks | 13% | |
Other | 3% | |
When switching from 1-month LAI paliperidone palmitate (Invega Sustenna®) to AOM, concomitant oral aripiprazole medication for at least 2 weeks is recommended. | 80% | |
When switching from 3-month LAI paliperidone palmitate (Invega Trinza®) to AOM, the majority of experts recommended concomitant oral aripiprazole medication for at least 2 weeks. | Oral aripiprazole for at least 2 weeks | 70% |
No concomitant oral medication needed | 27% | |
Oral paliperidone for at least 2 weeks | 3% | |
Recommendation 8: Switching to AOM in stable patients on other LAIs for enhancing treatment effectiveness. | Practice Option | LoA |
At least 3–7 days of prior treatment with oral aripiprazole is recommended for patients who have never been treated with aripiprazole before. | 100% | |
The majority of experts recommended that the original LAI should be stopped upon initiating AOM treatment. | Stopped upon initiation of AOM | 77% |
Tapered following stable AOM use | 23% | |
The majority of experts recommended that AOM should be initiated to replace the next dose of the original LAI | Replace the next dose | 60% |
Prior to the next dose | 40% | |
The majority of experts recommended that the starting dose of AOM should be based on the dose of the original LAI (please see Table 3). | Based on the dose of the original LAI | 77% |
400 mg | 23% | |
When switching from LAI risperidone (Risperdal Consta®) to AOM, the majority of experts recommended concomitant oral aripiprazole medication for at least 2 weeks. | Oral aripiprazole for at least 2 weeks | 63% |
No concomitant oral medication needed | 30% | |
Oral risperidone for at least 2 weeks | 7% | |
When switching from 1-month LAI paliperidone palmitate (Invega Sustenna®) to AOM, the majority of experts recommended concomitant oral aripiprazole medication for at least 2 weeks. | Oral aripiprazole for at least 2 weeks | 70% |
No concomitant oral medication needed | 27% | |
Oral paliperidone for at least 2 weeks | 3% | |
When switching from 3-month LAI paliperidone palmitate (Invega Trinza®) to AOM, the majority of experts recommended concomitant oral aripiprazole medication for at least 2 weeks. | Oral aripiprazole for at least 2 weeks | 53% |
No concomitant oral medication needed | 47% | |
Recommendation 9: For pregnant or lactating patients on AOM. | ||
As the benefits of continuing treatment outweigh the risks, continued use of AOM is recommended for pregnant patients, and in addition to continuous monitoring, patients should be informed about relevant risks. | 80% | |
As the benefits of continuing treatment outweigh the risks, continued use of AOM is recommended for lactating patients, and in addition to continuous monitoring, patients should be informed about relevant risks. | 80% |
Medication | Daily Equivalent Dose |
---|---|
Oral antipsychotics | |
Amisulpride | 85.77 mg |
Aripiprazole | 1.84 mg |
Clozapine | Not available |
Lurasidone | 23.49 mg |
Olanzapine | 2.42 mg |
Paliperidone | 2.13 mg |
Quetiapine | 77.01 mg |
Risperidone | 1.00 mg |
Ziprasidone | 29.77 mg/d |
Long-acting injectable antipsychotics (LAI) | |
LAI Olanzapine | 3.16 mg |
LAI Paliperidone | 1.53 mg |
LAI Risperidone | 0.42 mg |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Liang, C.-S.; Su, T.-P.; Hsieh, M.-H.; Lee, C.-S.; Kuo, J.; Chiu, N.-Y.; Chen, P.-S.; Yen, Y.-C.; Bai, Y.-M. Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia. J. Pers. Med. 2021, 11, 1198. https://doi.org/10.3390/jpm11111198
Liang C-S, Su T-P, Hsieh M-H, Lee C-S, Kuo J, Chiu N-Y, Chen P-S, Yen Y-C, Bai Y-M. Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia. Journal of Personalized Medicine. 2021; 11(11):1198. https://doi.org/10.3390/jpm11111198
Chicago/Turabian StyleLiang, Chih-Sung, Tung-Ping Su, Ming-Hsien Hsieh, Chau-Shoun Lee, Joseph Kuo, Nan-Ying Chiu, Po-See Chen, Yung-Chieh Yen, and Ya-Mei Bai. 2021. "Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia" Journal of Personalized Medicine 11, no. 11: 1198. https://doi.org/10.3390/jpm11111198